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Rheb is a Critical Regulator of Autophagy During
Myocardial Ischemia
Pathophysiological Implications in Obesity and Metabolic Syndrome
Sebastiano Sciarretta, MD; Peiyong Zhai, MD, PhD; Dan Shao, BS;
Yasuhiro Maejima, MD, PhD; Jeffrey Robbins, PhD; Massimo Volpe, MD;
Gianluigi Condorelli, MD, PhD; Junichi Sadoshima, MD, PhD
Background—Rheb is a GTP-binding protein that promotes cell survival and mediates the cellular response to energy
deprivation (ED). The role of Rheb in the regulation of cell survival during ED has not been investigated in the heart.
Methods and Results—Rheb is inactivated during cardiomyocyte (CM) glucose deprivation (GD) in vitro, and during acute
myocardial ischemia in vivo. Rheb inhibition causes mTORC1 inhibition, because forced activation of Rheb, through
Rheb overexpression in vitro and through inducible cardiac-specific Rheb overexpression in vivo, restored mTORC1
activity. Restoration of mTORC1 activity reduced CM survival during GD and increased infarct size after ischemia, both
of which were accompanied by inhibition of autophagy, whereas Rheb knockdown increased autophagy and CM
survival. Rheb inhibits autophagy mostly through Atg7 depletion. Restoration of autophagy, through Atg7 reexpression
and inhibition of mTORC1, increased cellular ATP content and reduced endoplasmic reticulum stress, thereby reducing
CM death induced by Rheb activation. Mice with high-fat diet–induced obesity and metabolic syndrome (HFD mice)
exhibited deregulated cardiac activation of Rheb and mTORC1, particularly during ischemia. HFD mice presented
inhibition of cardiac autophagy and displayed increased ischemic injury. Pharmacological and genetic inhibition of
mTORC1 restored autophagy and abrogated the increase in infarct size observed in HFD mice, but they failed to protect
HFD mice in the presence of genetic disruption of autophagy.
Conclusions—Inactivation of Rheb protects CMs during ED through activation of autophagy. Rheb and mTORC1 may
represent therapeutic targets to reduce myocardial damage during ischemia, particularly in obese patients. (Circulation.
2012;125:1134-1146.)
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Heart failure is viewed as one of the major healthcareproblems worldwide, with acute myocardial infarction
(MI) as the most common predisposing cause.1 It is funda-
mental to clarify the mechanisms regulating cardiomyocyte
(CM) death and survival during ischemic injury to find new
therapies to reduce the amount of myocardial loss after a
sudden coronary occlusion.
Clinical Perspective on p 1146
Ras homology enriched in brain (Rheb) is a small GTP-
binding protein that has been shown to regulate the cellular
stress response, both in lower organisms and in mammalian
cell lines. In particular, Rheb appears to be a critical sensor of
energy stress, being inactivated under this condition. Inhibi-
tion of Rheb during cellular stress promotes the upregulation
of adaptive mechanisms, such as cell cycle arrest and growth
inhibition, which may save energy, favor DNA repair, and
thus be protective.2–4 On the contrary, Rheb is hyperactivated
in cancer cells, where it promotes stress resistance and
survival, and Rheb activation was found to directly inhibit
apoptotic pathways induced by amino acid deprivation and
genotoxic stress.5,6 Therefore, it is not clear whether Rheb
activity is protective or detrimental during cellular stress.
Remarkably, the role of Rheb in response to acute energy
deprivation, and in regulation of cell death and survival, has
never been investigated in the heart.
Rheb activity is regulated by upstream kinases, such as
Akt, AMP-activated protein kinase (AMPK), and glycogen
Received August 15, 2011; accepted January 23, 2012.
From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey,
New Jersey Medical School, Newark, NJ (S.S., P.Z., D.S., Y.M., J.S.); IRCCS Neuromed, Pozzilli (IS), Italy (S.S., M.V.); Molecular Cardiovascular
Biology, Heart Institute, Cincinnati Children’s Hospital, Cincinnati, OH (J.R.); Cardiology Department, IInd School of Medicine, University of Rome
“Sapienza,” S. Andrea Hospital, Rome, Italy (M.V.); and Department of Medicine, University of California San Diego, La Jolla, CA (G.C.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.
078212/-/DC1.
Correspondence to Junichi Sadoshima, MD, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey
Medical School, 185 South Orange Ave, Medical Science Building G-609, Newark, NJ 07103. E-mail Sadoshju@umdnj.edu
© 2012 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.111.078212
1134 by MASSIMO BOTTICELLI on April 24, 2012http://circ.ahajournals.org/Downloaded from 
synthase kinase-3, which control Rheb through direct mod-
ulation of the heterodimer composed of the tuberous sclerosis
complex proteins 1 (TSC1) and 2 (TSC2). The TSC1/TSC2
complex inhibits Rheb by exerting a strong GTPase activity
toward it.2,7 Rheb directly binds and selectively activates the
multiprotein complex 1 of mammalian target of rapamycin
(mTORC1), which in turn mediates many cellular functions,
such as protein translation.8 mTORC1 is also inhibited in
response to energy stress, and its inactivation reduces protein
synthesis and upregulates autophagy.8 However, mTORC1
activation also promotes cell survival and inhibits apoptosis
in several stress conditions, and, therefore, whether mTORC1
inhibition is detrimental or protective during cellular stress is
stimulus dependent.5,8
The role of mTORC1 in mediating survival and death of
CMs has only been investigated in models of chronic cardiac
remodeling, with discordant results.9–11 Importantly, the ef-
fect of direct and selective mTORC1 versus mTORC2 mod-
ulation during CM acute energy deprivation, such as myocar-
dial ischemia, remains to be elucidated. It is also unclear how
mTORC1 is modulated during CM energy deprivation and
whether Rheb, an immediate upstream regulator of mTORC1,
is critically involved in such regulation in CMs.
In our study, we investigated the role of Rheb in the
regulation of cell death and survival during CM starvation
and ischemia, and the underlying molecular mechanisms. In
particular, we studied whether a direct and selective modu-
lation of mTORC1 induced by Rheb is involved in the effects
exerted by Rheb on CM survival during energy stress. Recent
reports have shown that obesity and metabolic syndrome,
which are characterized by an increased risk of cardiovascu-
lar mortality12 and increased myocardial susceptibility to
ischemic injury,13–16 are associated with a hyperactivation of
tissue mTORC1.17,18 Therefore, we also evaluated whether
cardiac mTORC1 is activated in obesity and metabolic
syndrome, whether Rheb is involved in such phenomena, and
whether a deregulated activation of Rheb and mTORC1 may
be responsible for the increased susceptibility to ischemia
associated with these conditions.
Methods
Experimental Procedures
Experimental procedures and animal models are described in the
expanded Methods section in the online-only Data Supplement.
Experimental procedures, heterozygous GFP-LC3 transgenic mice,
beclin-1 knockout mice, and conditional mTOR knockout mice have
also been described elsewhere.9,19,20 All experimental procedures
with animals were approved by the Institutional Animal Care and
Use Committee of the University of Medicine and Dentistry of New
Jersey.
Statistics
Data are expressed as meanSEM. When specified in the figure
legends, presentation of bar charts was standardized by control
mean100, so that the presented bars represent the mean percentage
of variationSEM, with respect to the control mean. The difference
in means between 2 groups was evaluated using the t test when
sample size was appropriate and the population was normally
distributed; otherwise, the Mann-Whitney U test was adopted. When
differences among 3 or more groups were evaluated, the one-way
analysis of variance or the Kruskal-Wallis test was used. The post
hoc comparisons were performed by use of the Bonferroni post hoc
test or the Mann-Whitney U test with Bonferroni correction. The
shown statistical significance of differences between groups was
always calculated by post hoc comparisons when multiple groups
were compared. Statistical analyses were performed with the use of
SPSS 15.0 (SPSS Inc, Chicago, IL) and GraphPad-Prism 5.00
(GraphPad-Software, San Diego, CA). Probability values of 0.05
were considered statistically significant.
Results
Rheb Mediates mTORC1 Inhibition During
Starvation in CMs
To investigate whether Rheb acts as a sensor of energy
deprivation in CMs, neonatal rat ventricular CMs were
subjected to glucose deprivation (GD). GTP binding of Rheb
was decreased significantly in response to GD (Figure 1A),
indicating that Rheb is inactivated by GD. During GD,
phosphorylation of p70S6K and 4E-BP1 was progressively
reduced, indicating that mTORC1 was inhibited (Figure 1B).
Knockdown of Rheb, with adenovirus harboring shRNA-
Rheb, inhibited phosphorylation of p70S6K at baseline, sug-
gesting that inactivation of Rheb is sufficient to inactivate
mTORC1 (online-only Data Supplement Figure IA). Trans-
duction of CMs with adenovirus harboring wild-type Rheb
abolished the GD-induced decreases in phosphorylation of
p70S6K and 4E-BP1 (Figure 1C through 1E and online-only
Data Supplement Figure IB), suggesting that Rheb inactiva-
tion is required for GD-induced suppression of mTORC1. In
addition, Rheb physically interacts with mTOR both at
baseline and during GD (online-only Data Supplement
Figure IC), thus indicating that Rheb directly regulates
mTORC1 in CMs.
Rheb is negatively regulated by the GTPase-activating
protein activity of the TSC1/TSC2 complex.7 Downregu-
lation of TSC2, with adenovirus harboring shRNA-TSC2
(online-only Data Supplement Figure ID), induced phos-
phorylation of p70S6K, suggesting that endogenous TSC2
negatively regulates mTORC1 in CMs (online-only Data
Supplement Figure IE and IF). Activation of mTORC1 by
downregulation of TSC2 was abolished in the presence of
Rheb knockdown, suggesting that TSC2 regulates
mTORC1 through Rheb (online-only Data Supplement
Figure IE and IF). On the other hand, as indicated by the
phosphorylation status of Akt, the activity of mTORC2,
another branch of the mTOR pathway, was unaffected by
GD, and overexpression of Rheb failed to activate Akt
(online-only Data Supplement Figure IG and IH). These
results suggest that GD inhibits mTORC1, but not
mTORC2, by inactivating Rheb.
Activation of Rheb Sensitizes CMs to Cell Death
During GD, Whereas Inhibition Is Protective
We then investigated the role of Rheb in regulating CM
survival during GD. Although Rheb is cell protective in other
cell types, CMs in which the activity of mTORC1 was
normalized with overexpressed Rheb displayed decreased
survival after 10 and 18 hours of GD in comparison with
control virus–treated CMs (Figure 2A). CMs overexpressed
with Rheb displayed significantly more apoptosis and necro-
sis, as assessed by TdT-mediated dUTP nick-end labeling
(TUNEL) assays and propidium iodide staining, respectively
Sciarretta et al Rheb and Cardiomyocyte Energy Stress 1135
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(Figure 2B and 2C, online-only Data Supplement Figure IIA).
TSC2 knockdown also decreased survival and increased
apoptosis of CMs in response to GD (Figure 2D and online-
only Data Supplement Figure IIB). Conversely, downregula-
tion of endogenous Rheb increased the survival of CMs
during GD and rescued the decrease in cell survival in the
presence of TSC2 knockdown during GD (Figure 2E).
Furthermore, selective inhibition of mTORC1, through Rap-
tor downregulation, with adenovirus harboring shRNA-
Raptor, significantly increased CM survival during GD in
Rheb-overexpressing CMs. In contrast, selective mTORC2
inhibition, through Rictor depletion, did not increase survival
in Rheb-overexpressing CMs during GD (Figure 2F). Collec-
tively, these data suggest that Rheb negatively regulates CM
survival during GD through mTORC1 activation. Thus,
inactivation of endogenous Rheb during GD is an adaptive
mechanism that promotes survival of CMs.
Rheb Regulates CM Autophagy
We investigated the molecular mechanism through which inac-
tivation of Rheb protects CMs during GD. Because Rheb
inactivation causes mTORC1 inhibition during GD, and because
mTOR is a negative regulator of autophagy,21 we hypothesized
that downregulation of Rheb during GD is required for stimu-
lation of autophagy, which may be protective in this context.19
As shown previously, GD increased LC3-II and decreased p62,
a protein degraded by autophagy,21 suggesting that GD activates
autophagy in CMs. However, in Rheb-overexpressing CMs,
LC3-II expression was lower and expression of p62 was
greater, both at baseline and during GD (Figure 3A
through 3C). The number of GFP-LC3 dots, an indicator of
autophagosome accumulation, during GD was signifi-
cantly smaller in Rheb-overexpressing CMs than in control
CMs (Figure 3D and 3E). Rheb overexpression induced
significant downregulation of autophagy genes, including
beclin-1, ulk-1, atg4, and atg7 (Figure 3F). Conversely,
downregulation of endogenous Rheb significantly in-
creased autophagy at baseline and during GD (online-only
Data Supplement Figure III). These results suggest that
endogenous Rheb negatively regulates autophagy and that
inactivation of Rheb is necessary and sufficient for stim-
ulation of autophagy in CMs during GD.
Figure 1. mTORC1 is downregulated dur-
ing GD through Rheb inactivation. A,
Rheb activity was assessed by the ratio
of Rheb-bound GTP to Rheb-bound
GTPGDP levels at baseline and during
GD; n5. B, CMs were subjected to GD
for different periods of time. Phosphoryla-
tion statuses of p70S6K (Thr 389) and
4E-BP1 (Thr 37/46) were evaluated. C
through E, CMs were transduced with
adenovirus harboring wild-type Rheb or
LacZ. After 48 hours, phosphorylation
statuses of p70S6K and 4E-BP1 were
evaluated at baseline and after GD. Im-
munoblots and densitometric analyses are
presented. n5. GD indicates glucose
deprivation; CM, cardiomyocyte.
1136 Circulation March 6, 2012
 by MASSIMO BOTTICELLI on April 24, 2012http://circ.ahajournals.org/Downloaded from 
We then asked if autophagy mediates the cell-protective
effect of Rheb inactivation. The protective effect of Rheb
downregulation during GD was completely abrogated when
Beclin-1 was downregulated with adenovirus harboring
shRNA-beclin1 (Figure 3G). These results suggest that au-
tophagy plays an important role in mediating the protective
effect of Rheb inactivation during GD. Conversely, to restore
autophagy during GD in Rheb-overexpressing CMs, we
expressed Atg7 with adenovirus transduction (online-only
Data Supplement Figure IVA). We took this approach be-
cause Atg7 is a crucial protein for autophagosome formation,
because Atg7 is markedly downregulated in Rheb-
overexpressing CMs, and because overexpression of Atg7 is
sufficient to reinduce autophagy when autophagy is inhib-
ited.21,22 Atg7 overexpression significantly restored au-
tophagy in Rheb-overexpressing CMs during GD (online-
only Data Supplement Figure IVB through IVD). We also
used trehalose, which induces autophagy without affecting
the mTORC1 pathway.23 Trehalose restored Atg7 and
Beclin-1 expression in Rheb-overexpressing CMs without
affecting the mTORC1 pathway, thereby restoring autophagy
during GD (online-only Data Supplement Figure IVE and
IVF). Importantly, both Atg7 expression and trehalose pre-
treatment significantly increased the survival of Rheb-
overexpressing CMs during GD (Figure 3H). Collectively,
these results suggest that Rheb regulates the survival and
death of CMs during GD through regulation of autophagy in
vitro.
Rheb Overexpression Increases Energy Stress and
Endoplasmic Reticulum Stress During GD
Important consequences of autophagy include restoration of
ATP contents and protein quality control. Rheb overexpres-
sion during GD significantly enhanced ATP depletion,
whereas Rheb disruption significantly increased ATP content
(Figure 4A). Overexpression of Rheb increased GRP78,
phosphorylation of protein kinase RNA-like endoplasmic
reticulum kinase and upregulation of Ccaat-enhancer-binding
protein homologous protein (CHOP), and Caspase-12 (frag-
ment), markers of endoplasmic reticulum (ER) stress, in CMs
during GD (Figure 4B and 4C). Conversely, upregulation of
the ER stress markers during GD was significantly attenuated
in CMs in which Rheb was knocked down (Figure 4B and
4C). Restoration of autophagy in Rheb-overexpressing CMs,
Figure 2. Rheb activation during GD
increases CM death and apoptosis. A,
Cell viability was evaluated in CMs trans-
duced with Ad-Rheb or Ad-LacZ at base-
line and during GD. n4. B and C, Per-
centage of TUNEL-positive cells was also
evaluated after GD. n4, bar50 m. D,
CMs were transduced with Ad harboring
sh-RNA-TSC2 or with sh-scramble. After
96 hours, cell viability was evaluated at
baseline and after GD. n5. E, Cell viabil-
ity was evaluated in CMs transduced with
sh-scramble (sh-CT), sh-Rheb, sh-TSC2,
or sh-Rheb plus sh-TSC2 at baseline and
after GD. n5. F, Cell viability was evalu-
ated in CMs transduced with Ad-LacZ,
Ad-Rheb, or Ad-Rheb plus sh-Raptor or
sh-Rictor, at baseline and after GD. n3.
Cell viability was assessed by Cell Titer
Blue assay. Data are presented as a per-
centage of the relevant control (regular
medium), with the control being set at
100%. *P0.05 with respect to relevant
control (regular medium). Ad indicates
adenovirus; sh, short hairpin; GD, glucose
deprivation; CM, cardiomyocyte; DAPI,
4,6-diamidino-2-phenylindole-2-HCl;
TUNEL, TdT-mediated dUTP nick-end
labeling.
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through Atg7 overexpression, significantly attenuated ATP
depletion (Figure 4D) and ER stress during GD, indicating
that autophagy inhibition is responsible for these derange-
ments (Figure 4E and 4F).
Inhibition of Rheb Is Protective During Prolonged
Myocardial Ischemia
To investigate the role of Rheb in regulating CM survival and
death in response to energy deprivation in vivo, we used a
mouse model of prolonged ischemia, in which the left
descending coronary artery was ligated for 3 hours. During
ischemia, the GTP-bound form of Rheb was significantly
decreased, whereas the total expression of Rheb was not
altered, suggesting that Rheb is inactivated by prolonged
ischemia in vivo (Figure 5A and 5B). The activity of
mTORC1, as evaluated with p70S6K phosphorylation, was
also decreased during ischemia (Figure 5C and 5D).
To evaluate the significance of Rheb inhibition during
ischemia in vivo, we generated transgenic mice with cardiac-
specific overexpression of Rheb (Tg-Rheb) with use of a
Tet-off system. In these mice, expression of the Rheb
transgene in the heart was induced in the absence of doxy-
cycline. Doxycycline was administered to the mice during the
gestational period and for the first 3 to 4 weeks of life to avoid
Figure 3. Rheb is a negative regulator of autophagy. A through C, CMs were transduced with Ad-LacZ or Ad-Rheb for 48 hours.
LC3 isoforms and p62 accumulation were evaluated at baseline or after 4 hours of GD. A representative immunoblot is shown (A),
together with densitometric analyses of LC3-II (B) and p62 (C). n5. D and E, CMs were transduced with Ad-GFP-LC3 together
with Ad-LacZ or Ad-Rheb. GFP-LC3 puncta were evaluated after 4 hours of GD (bar10 m). n3. F, Expression of autophagic
genes was evaluated in CMs transduced with Ad-LacZ or Ad-Rheb. G, Cell viability was evaluated in CMs transduced with
sh-scramble, sh-Rheb, or with sh-Rheb plus sh-Beclin-1. n4. Data are presented as a percentage of the relevant CT (baseline),
with CT being set at 100%. H, Cell viability was evaluated in CMs transduced with Ad-LacZ, Ad-Rheb, and with Ad-Rheb
together with Ad-Atg7 or trehalose. Sucrose treatment (100 mmol/L) was used as control treatment for trehalose. n3. Atg7Ad-
Atg7. Tre indicates trehalose; Ad, adenovirus; sh, short hairpin; GD, glucose deprivation; CM, cardiomyocyte; CT, control.
*P0.05 with respect to cells cultured with a normal medium.
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the effect of transgene expression during cardiac develop-
ment in Tg-Rheb (Figure 5E and online-only Data Supple-
ment Figure VA and VB). Doxycycline was terminated 6 to
8 weeks before the experiment to allow full transgene
expression and eliminate possible actions of doxycycline on
cell death/survival. In this protocol, expression of Rheb was
2.3-fold greater in Tg-Rheb than in control littermates
(Rheb/tTA mice). Rheb exhibited diffuse cytoplasmic
distribution in CMs of both control mice and Tg-Rheb
(online-only Data Supplement Figure VC and VD). Tg-Rheb
presented a normal cardiac phenotype at 3 months of age
(online-only Data Supplement Table I). In Tg-Rheb mice,
mTORC1 activity was significantly increased, both at base-
line and during prolonged ischemia, in comparison with
control mice (Figure 5C and 5D), suggesting that Rheb
inactivation is required for mTORC1 inhibition during pro-
longed ischemia. After 3 hours of ischemia, Tg-Rheb mice
exhibited a significantly greater MI size than control mice
(Figure 5F through 5H). The extent of CM apoptosis and
necrosis after prolonged ischemia was also greater in Tg-
Rheb than in controls, as evaluated with TUNEL and
Hairpin-2 staining, respectively (online-only Data Supple-
ment Figure VI). Tg-Rheb presented increased ischemic
injury even after a brief period of ischemia (30 minutes), as
evaluated with Hairpin-2 staining. Tg-Rheb also exhibited
significantly enhanced myocardial damage even after a lon-
ger coronary occlusion (6 hours; online-only Data Supple-
ment Figure VII).
There was less induction of autophagy in Tg-Rheb than
in control mice at baseline and during ischemia, as
indicated by reduced LC3-II and increased p62 accumula-
tion (online-only Data Supplement Figure VIIIA through
VIIIC). Expression of p62 did not differ at the mRNA level
between controls and Tg-Rheb, indicating that increased
p62 accumulation was due to reduced degradation (mRNA
expression in Tg-Rheb 0.96-fold versus controls, PNS).
The level of myocardial ATP in the ischemic area after
ischemia was significantly lower in Tg-Rheb than in
controls (online-only Data Supplement Figure VIIID). The
level of CHOP, an indicator of ER stress, after ischemia
was also significantly greater in Tg-Rheb than in control
mice (online-only Data Supplement Figure VIIIE and
Figure 4. Rheb activation increases ATP
depletion and ER stress during GD. A,
CM ATP content at baseline and after 18
hours of GD was evaluated in CMs with
Rheb overexpression or depletion. Data
are presented as the fluorescence of each
sample as a percentage of the control.
*P0.05 vs control (regular medium).
n4. B and C, Unfolded protein response
markers were evaluated at baseline and
after GD. *P0.05 vs LacZ after GD. n5.
D through F, ATP content (D, n5) and
GRP78 accumulation (E and F, n3) were
evaluated in Rheb-overexpressing CMs
with or without Ad-Atg7, after GD. Ad
indicates adenovirus; sh, short hairpin;
GD, glucose deprivation; CM, cardiomyo-
cyte; CHOP, C/EBP homologous protein.
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VIIIF). These results indicate that inhibition of endoge-
nous Rheb is protective during prolonged ischemia in vivo.
To evaluate whether the deleterious effect of Rheb
overexpression during prolonged ischemia is due to the
lack of mTORC1 inactivation and activation of autophagy,
rapamycin, a selective inhibitor of mTORC1 and stimula-
tor of autophagy, was administered to Tg-Rheb and control
mice just before the prolonged ischemia. Rapamycin in-
hibited mTORC1 activity and stimulated autophagy in
Tg-Rheb mice after prolonged ischemia (Figure 6A).
Rapamycin significantly reduced the size of MI in re-
sponse to prolonged ischemia in Tg-Rheb mice in compar-
ison with vehicle administration (Figure 6B through 6D).
Rapamycin treatment also significantly reduced CHOP
accumulation and caspase-3 cleavage in Tg-Rheb hearts
after prolonged ischemia (Figure 6E and 6F). These results
suggest that Rheb promotes myocardial injury during
prolonged ischemia by stimulating mTORC1, inhibiting
autophagy and stimulating ER stress.
High-Fat Diet–Induced Obesity Is Associated With
Deregulation of Rheb and Increased Myocardial
Susceptibility to Prolonged Ischemia
Obesity and metabolic syndrome are associated with high
cardiovascular mortality and reduced cardiac function after
MI.12–16 Complications of obesity are associated with dereg-
ulated mTORC1 activation and inhibition of autophagy in
other organs.17,18,22 We therefore investigated whether obesity
is associated with deregulated Rheb activation, which in turn
mediates an increased susceptibility to myocardial ischemia.
To induce obesity, C57BL/6J mice were fed with high-
fat diet (HFD) mice for 18 to 20 weeks. HFD mice
developed obesity and exhibited a significant increase in
serum levels of glucose, cholesterol, triglycerides, and
nonesterified fatty acid in comparison with mice fed with
control diet (CD) mice, suggesting that HFD mice develop
metabolic syndrome (online-only Data Supplement Table
II). Insulin levels and the HOMA index were significantly
elevated in HFD mice, consistent with the notion that these
Figure 5. Rheb activation is detrimental
during prolonged myocardial ischemia in
vivo. A, Rheb-bound GTP levels were
evaluated at baseline and after 30 min-
utes of ischemia. n7. B, The amount of
Rheb expression was evaluated at base-
line and during ischemia. C and D, Car-
diac p70S6K phosphorylation was evalu-
ated in Tg-Rheb mice and controls, both
at baseline and after 30 minutes of ische-
mia. n4 for each group. E, Cardiac
Rheb expression was evaluated in
Tg-Rheb mice and control mice (FVB
background). F through H, Tg-Rheb and
control mice (Rheb/tTA and Rheb-/
tTA) were subjected to 3 hours of ische-
mia. Left ventricular myocardial sections
after Alcian blue and triphenyltetrazolium
chloride staining is shown (F; bar1 mm),
as well as the AAR (G) and MI size/AAR
(H) quantification. AAR indicates area at
risk; MI, myocardial infarct; CT, control.
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mice develop insulin resistance. HFD mice presented
increases in mTOR-dependent IRS-1 phosphorylation (ser-
ine 636), which is a marker of decreased insulin sensitiv-
ity18 at baseline (online-only Data Supplement Figure
IXA). HFD mice showed a significant increase in left
ventricular mass and left ventricular wall thickness but
preserved left ventricular systolic function (online-only
Data Supplement Table III). Both cell size and expression
of atrial natriuretic factor, a fetal-type gene, were in-
creased, suggesting that HFD mice develop cardiac hyper-
trophy (online-only Data Supplement Figure IXB through
IXD). After prolonged (3 hours) ischemia, HFD mice
exhibited a significantly greater MI size than CD mice
(Figure 7A through 7C), which was accompanied by
greater numbers of TUNEL-positive and Hairpin-2-
positive cells (online-only Data Supplement Figure X),
signifying that HFD increases myocardial susceptibility to
ischemic injury. HFD mice also presented a greater per-
centage of hairpin-2–positive cells with respect to control
mice after 30 minutes of ischemia (11.51.3% versus
4.21.0%, P0.05).
In HFD mice, the activity of mTORC1 was greater at
baseline and remained elevated during prolonged ischemia
(Figure 7D and online-only Data Supplement Figure XIA).
Thus, the suppression of mTORC1 in response to pro-
longed ischemia observed in CD mice was attenuated in
HFD mice. Although the GTP-bound form of Rheb was
significantly reduced during prolonged ischemia in CD
mice, it was increased at baseline and not significantly
diminished during prolonged ischemia in HFD mice (Fig-
ure 7E), suggesting that the activity of Rheb and mTORC1
is elevated at baseline and remains greater in HFD mice
than in CD mice during prolonged ischemia. Intriguingly,
the activity of AMPK, a negative regulator of the Rheb/
mTORC1 pathway, was reduced in HFD mice both at
baseline and during ischemia, as indicated by a reduction
in its phosphorylation status. Conversely, it was activated
in CD mice during ischemia (Figure 7D and online-only
Data Supplement Figure XIA).
Consistent with activation of the mTORC1 pathway, au-
tophagy in the heart was significantly suppressed in HFD
mice both at baseline and during ischemia, as indicated by
decreased LC3-II and increased p62 accumulation (Figure 7F,
online-only Data Supplement Figure XIB and XIC). p62
mRNA expression was unchanged (0.84-fold versus CD
Figure 6. Rapamycin-induced autophagy
limits myocardial damage in Rheb-
overexpressing mice. A, Rapamycin (1
mg/kg) was administered intraperitoneally
to Tg-Rheb and control mice (Rheb/
tTA) 60 minutes before coronary liga-
tion. p70S6K phosphorylation and LC3
expression levels were evaluated after 30
minutes of ischemia, whereas p62
expression levels were evaluated after 3
hours of ischemia. B through D, The MI/
AAR ratio in Tg-Rheb and controls
treated, or not treated, with rapamycin
was evaluated. Bar1 mm. E and F,
CHOP expression and caspase-3 cleav-
age were also evaluated after 3 hours of
ischemia. n3 for each group. AAR indi-
cates area at risk; MI, myocardial infarct;
CT, control; CHOP, C/EBP homologous
protein,
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mice, PNS). Accumulation of autophagosomes, as evalu-
ated by use of GFP-LC3 dots, was significantly less in HFD
mice than in CD mice (Figure 7G and 7H). The number of
GFP-LC3 dots was significantly reduced in HFD mice during
ischemia, also after administration of chloroquine, which
inhibits lysosomal enzyme activity. These data indicate re-
duced autophagosome formation in HFD mice (online-only
Data Supplement Figure XID and XIE).
To investigate if deregulated activation of the mTORC1
pathway is responsible for the reduced tolerance to pro-
longed ischemia of HFD mice, we administered rapamycin
to these animals and evaluated its effect on ischemic
injury. As we observed with Tg-Rheb, rapamycin treat-
ment increased autophagy (online-only Data Supplement
Figure XIF) and significantly reduced the MI size of both
HFD mice and CD mice (Figure 8A through 8C). Rapa-
mycin administration failed to reduce ischemic injury in
heterozygous beclin-1 knockout mice (beclin-1/), in
which autophagy cannot be activated, when fed with HFD
(Figure 8D and 8E). These results indicate that autophagy
reactivation mediates the beneficial effect of mTORC1
inhibition in HFD mice.
Figure 7. HFD-induced obesity is associated with greater myocardial injury and deregulated Rheb/mTORC1 activation. A through C,
MI/AAR was evaluated in CD and HFD mice after ischemia. Bar1 mm. D, Phosphorylation statuses of p70S6K and AMPK (Thr 172)
were evaluated both at baseline and after 30 minutes of ischemia (densitometric analysis is shown in online-only Data Supplement Fig-
ure XIA). E, Myocardial Rheb-bound GTP content was evaluated in CD and HFD mice, both at baseline and after 30 minutes of ische-
mia. n5 for each group. F, Myocardial autophagy in HFD mice was significantly inhibited in comparison with control mice, both at
baseline and after 30 minutes (LC3-II levels) or 3 hours of ischemia (p62 levels). Representative immunoblots are presented, and densi-
tometric analysis is reported in online-only Data Supplement Figure XIB and XIC. G and H, Tg-GFP-LC3 mice fed with CD or HFD were
subjected to ischemia. Representative heart sections are shown. Bar50 m. Arrows indicate autophagosomes (G). The number of
autophagosomes per microscopic field in the 2 groups after 30 minutes of ischemia is reported (H). n4 each group. HFD indicates
high-fat diet; CD, control diet; AAR, area at risk; MI, myocardial infarct.
1142 Circulation March 6, 2012
 by MASSIMO BOTTICELLI on April 24, 2012http://circ.ahajournals.org/Downloaded from 
To further demonstrate that deregulated mTORC1 activa-
tion increases the ischemic susceptibility of HFD mice, we
subjected mice, with inducible cardiac-specific heterozygous
mTOR knockout, that were fed with HFD, to prolonged
ischemia. This strategy allowed us to partially inhibit the
mTOR pathway and to normalize the increased activation of
mTORC1 observed in HFD mice. Tamoxifen was adminis-
tered to -myosin heavy chain promoter-MerCreMer-mTOR
flox/ mice (mTOR/) for 7 days. Cardiac mTOR protein
levels were reduced in mTOR/ mice 3 weeks after
tamoxifen administration (online-only Data Supplement Fig-
ure XIIA). Cardiac mTOR deletion reduced mTORC1 activity
and increased autophagy in mTOR/ mice fed with control
diet or HFD (online-only Data Supplement Figure XIIB
through XIID). Remarkably, cardiac mTOR deletion reduced
MI size in mice fed with control diet and HFD with respect to
controls (Figure 8F through 8H). In summary, cardiac acti-
vation of the Rheb-mTORC1 pathway in HFD-induced obe-
sity is detrimental during prolonged ischemia because of the
inhibition of autophagy.
Discussion
We have demonstrated that Rheb is inhibited in response to
GD and prolonged ischemia, and inhibition of Rheb, in
turn, inhibits mTORC1 in CMs. Forced activation of Rheb
in such conditions stimulates ATP depletion and ER stress
by suppression of autophagy, thereby inducing cell death.
Thus, Rheb acts as a sensor of energy stress and as a
critical regulator of CM survival in response to energy
starvation.
We have shown previously that both GD and ischemia in
CMs and in the heart, respectively, induce suppression of
mTOR.19,20 It should be noted that mTOR is inhibited by
both Rheb-dependent and -independent mechanisms.19,20
For example, several upstream kinases, including AMPK
and glycogen synthase kinase-3, which indirectly regu-
Figure 8. mTORC1 inhibition is protective
in HFD mice through autophagy activa-
tion. A through C, Rapamycin (1 mg/kg)
was administered intraperitoneally to HFD
and CD mice 60 minutes before coronary
ligation. Mice were subjected to 3 hours
of ischemia. The MI/AAR ratio was evalu-
ated. Bar1 mm. *P0.05 vs CD. D and
E, Either control or beclin-1/ mice fed
with HFD were subjected to 3 hours of
ischemia. The MI/AAR ratio was evalu-
ated. R indicates rapamycin. F through H,
After feeding with HFD or CD, tamoxifen
(30 mg/kg) was administered to -MHC-
MerCreMer-mTOR flox/ mice
(mTOR/) and -MHC-MerCreMer-
mTOR / mice (controls) for 7 days.
The mice were subjected to 3 hours of
ischemia. The MI/AAR ratio was evalu-
ated. HFD indicates high-fat diet; CD,
control diet; AAR, area at risk; MI, myo-
cardial infarct; MHC, myosin heavy chain.
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late mTOR, inhibit Rheb through phosphorylation and
consequent activation of GTPase-activating protein activ-
ity in TSC2.2,3,8 It should be noted, however, that mTOR is
also inhibited through Rheb-independent mechanisms,
such as Akt-dependent phosphorylation of mTOR and
PRAS40, and AMPK-dependent Raptor phosphorylation.8
Our results indicate that Rheb interacts with mTOR, that
Rheb is inhibited during GD and myocardial ischemia, and
that its inactivation is required for mTORC1 inhibition.
Conversely, neither overexpression of Rheb nor GD af-
fected the activity of mTORC2. We therefore propose that
Rheb acts as a central and direct regulator of mTORC1
during energy starvation in CMs.
Our results suggest that forced Rheb activation exacerbates
cell death and apoptosis during GD and prolonged ischemia,
but it does not affect cell survival at baseline. On the other
hand, downregulation of Rheb increased survival of CMs
during GD, intimating the involvement of endogenous Rheb
in the regulation of survival/death during GD and prolonged
ischemia. Previous studies have indicated that Rheb promotes
cell survival and inhibits apoptotic cell death in response to
stress in several cancer cells.5,6 Activation of Rheb in un-
stressed conditions also induces hypertrophy without cell
death in CMs (not shown). Thus, the function of Rheb in cells
appears to be context dependent.
Importantly, we found that downregulation of mTORC1
mediates the protective effects of Rheb inhibition during
energy deprivation, because depletion of Raptor but not of
Rictor, which are the adaptor proteins of complex 1 and
complex 2 of mTOR, respectively, increased survival of
Rheb-overexpressing CMs during GD in vitro. In addition,
pharmacological and genetic inhibition of mTORC1 reduced
the susceptibility to ischemic myocardial damage of Rheb-
overexpressing and obese mice, and a protective effect was
also observed in control animals in vivo. These results
suggest that Rheb is an obvious therapeutic surrogate of
mTORC1, to achieve increased CM survival during energy
deprivation.
The role of mTOR in regulating the stress response is
poorly understood in terminally differentiated cell types
such as CMs. In particular, the role of mTOR in the
regulation of CM survival has been primarily investigated
through indirect means, eg, the use of pharmacological
inhibitors, which may have mTOR-independent ef-
fects.19,20 In addition, the role of mTOR in cardiac stress
has been mostly studied in animal models of chronic
ventricular remodeling in which mTORC1 is activated,
whereas we observed mTORC1 inhibition during CM
energy deprivation.9 –11 Interestingly, mTORC1 activation
has been indicated as protective during cardiac mechanical
overload.9,11 On the other hand, in our study, we demon-
strated that selective and direct mTORC1 activation is
detrimental during acute cardiac energy deprivation,
whereas both pharmacological and genetic mTORC1 inhi-
bitions are protective. In particular, we provided the first
evidence that genetic mTOR inhibition is protective during
myocardial ischemia. Thus, the function of mTORC1 in
CMs appears to be context dependent. mTORC1 activation
might be required for cell growth in response to mechan-
ical overload, whereas mTORC1 inhibition is important
for preservation of energy status in response to energy
deprivation.
Rheb inhibition during energy deprivation is required for
autophagy activation, which is protective in this condition. In
fact, suppression of autophagy by knockdown of Beclin-1
completely abrogated the protective effect of Rheb knock-
down in CMs during GD. Restoration of autophagy through
treatment with trehalose or overexpression of Atg7, which
stimulates autophagy through mTOR-independent mecha-
nisms, significantly reduced CM death induced by forced
Rheb activation. Therefore, although it is still debated
whether autophagy is protective or detrimental during cardiac
stress,24 we have demonstrated that Rheb-regulated au-
tophagy is protective during CM nutrient starvation and
ischemia. In particular, we showed that Rheb-regulated au-
tophagy is protective through the preservation of ATP content
and reduction of misfolded protein accumulation, namely ER
stress.
Rheb-induced inhibition of autophagy was accompanied
by downregulation of Atg7 protein levels. Overexpression of
Atg7 was sufficient to restore autophagy and to suppress
Rheb-induced cell death during GD, suggesting that Rheb
regulates autophagy, in part, through Atg7. mTORC1 was
suggested to modulate autophagy through Ulk1/2 regula-
tion.21 The role of Ulk1/2 in mediating expression of Atg7
remains to be elucidated.
Interestingly, inadvertent activation of the Rheb/mTORC1
pathway is observed in HFD-induced obesity. Obesity is
characterized by glucose intolerance and dyslipidemia, and it
is associated with an increased susceptibility to myocardial
ischemia.13–16 We demonstrated that autophagy is reduced in
the hearts of mice with HFD-induced obesity. These mice
exhibited exacerbated myocardial injury in response to pro-
longed ischemia, which was normalized by rapamycin treat-
ment or genetic mTOR inhibition, suggesting that increased
mTORC1 activity may be responsible for the increased
susceptibility. Remarkably, inhibition of Beclin-1 was asso-
ciated with the failure of pharmacological mTORC1 inhibi-
tion to reduce ischemic injury in HFD mice, indicating that
reactivation of autophagy is the crucial mechanism mediating
the beneficial effects of mTORC1 inhibition in HFD-induced
obesity.
Severe obesity and metabolic syndrome are associated with
increased cardiovascular risk events and a poor prognosis in
patients after acute MI.12,14,15,25,26 If our results hold true in
humans, it may be helpful to treat patients with obesity and
metabolic syndrome by use of pharmacological inhibitors of
Rheb or mTORC1 to stimulate autophagy during an acute
episode of myocardial ischemia. Our results are also sup-
ported by an interesting previous study that showed that
obesity increases vascular senescence and vascular dysfunc-
tion in response to mTOR activation.27
Other previous studies showed increased basal mTORC1
activity in the liver,17,28 adipose tissue,29 vasculature,27 skel-
etal muscle,17,28,30,31 and cardiac muscle32–34 in both genetic
and diet-induced models of obesity and dysmetabolic condi-
tions. AMPK inhibition has been proposed as the main
intracellular mechanism leading to mTORC1 activa-
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tion.18,30–34 Our study extends this previous evidence, sug-
gesting that Rheb is involved in the activation of mTORC1
induced by AMPK downregulation.
Several stimuli may enhance the activity of the Rheb/
mTORC1 pathway in the tissues of obese and dysmetabolic
animals. High caloric intake may represent one possible
cause. High levels of circulating and cardiac lipids may also
represent potential mechanisms. In addition, increases in
circulating insulin, amino acids, cytokines, and adipokines
may contribute to the increased Rheb/mTORC1 activity in
HFD mice.17,18,28,31,32,35
In summary, our study demonstrates that inactivation of
Rheb protects CMs during energy deprivation through acti-
vation of autophagy, reduction of energy expenditure, and
attenuation of ER stress (online-only Data Supplement Figure
XIIE). Rheb and mTORC1 may represent therapeutic targets
to reduce myocardial damage during acute myocardial ische-
mia, particularly in patients with obesity and metabolic
syndrome.
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CLINICAL PERSPECTIVE
The incidence of heart failure after acute myocardial infarction (MI) remains very high in patients. This highlights the
necessity to clarify the mechanism regulating the survival and death of cardiomyocytes in response to ischemia and to find
new cardioprotective therapies reducing ischemic injury. We discovered that Rheb, a small GTP-binding protein, plays a
pivotal role in regulating the survival of cardiomyocytes during prolonged myocardial ischemia. Rheb activity is reduced
in the ischemic heart, thereby causing the suppression of the mTORC1 pathway. Inhibition of the Rheb/mTORC1 pathway
is an adaptive response during ischemia, because forced restoration of cardiac Rheb activity is detrimental under this
condition. Rheb inhibition is required for the activation of autophagy, an intracellular degradation process for proteins and
organelles, which is protective during energy stress through preservation of cellular energy and relief of ER stress. We
discovered that obesity and metabolic syndrome (Ob/MS) are associated with cardiac activation of Rheb/mTORC1 at
baseline and during ischemia. In obese mice, autophagy in the heart was suppressed and ischemic injury was exacerbated.
Remarkably, inhibition of mTORC1 restores autophagy and reduces infarct size in these animals after prolonged ischemia.
Thus, our results suggest that Rheb and mTORC1 may be promising therapeutic targets to reduce myocardial damage after
prolonged ischemia in patients with Ob/MS who display deregulated activation of the Rheb/TORC1 pathway and
consequent inhibition of autophagy.
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
Primary cultures of neonatal rat ventricular cardiomyocytes and reagents 
Primary cultures of ventricular cardiomyocytes were prepared from 1-day-old Crl: (WI) BR Wistar 
rats (Charles River Laboratories). A cardiomyocyte-rich fraction was obtained by centrifugation 
through a discontinuous Percoll gradient. Cells were cultured in a complete medium (cardiomyocyte) 
containing Dulbecco's modified Eagle's medium (DMEM)/F-12 supplemented with 5% horse serum, 4 
μg/ml transferrin, 0.7 ng/ml sodium selenite (Life Technologies, Inc.), 2 g/liter bovine serum albumin 
(fraction V), 3 mM pyruvic acid, 15 mM HEPES, 100 μM ascorbic acid, 100 μg/ml ampicillin, 5 μg/ml 
linoleic acid and 100 μM 5-bromo-2'-deoxyuridine (Sigma).  Trehalose and rapamycin were purchased 
from Sigma.  
Generation of Tg-Rheb mice 
A tetracycline-responsive binary α-MHC transgene system was used to allow temporally regulated 
expression of wild-type Rheb in cardiomyocytes 
1
. Mice were generated on a FVB background. 
Doxycycline was administered in the food with a special diet formulated by Purina (625 mg/kg in 
pellets). In the experiments that required Rheb protein induction, doxycycline was removed from the 
food at 3-4 weeks of life, resulting in induced expression of Rheb a few weeks later. All experimental 
procedures with animals were approved by the Institutional Animal Care and Use Committee of the 
University of Medicine and Dentistry of New Jersey. 
Construction of adenoviruses 
Recombinant adenovirus vectors were constructed as described 
2. pBHGloxΔE1,3Cre (Microbix), 
including the ΔE1 adenoviral genome, was co-transfected with the pDC shuttle vector containing the 
gene of interest into 293 cells. We made replication-defective human adenovirus type 5 (devoid of E1) 
harboring full length wild-type Rheb cDNA (Ad-Rheb) and full length wild-type Atg7 (Ad-Atg7), and 
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we used adenovirus harboring beta-galactosidase (Ad-LacZ) as a control. For the construction of short 
hairpin RNA (sh-RNA) adenoviral expression vectors, pSilencer 1.0-U6 expression vector was 
purchased from Ambion. The U6 RNA polymerase III promoter and the polylinker region were 
subcloned into the adenoviral shuttle vector pDC311 (Microbix). The hairpin-forming oligos of Rheb, 
Beclin-1, Raptor, Rictor and TSC2 rat cDNA and their antisenses with ApaI and Hind III overhangs 
were synthesized, annealed and subcloned distal to the U6 promoter. Recombinant adenoviruses were 
generated using homologous recombination in 293 cells. Cardiomyocytes were transduced with 
adenovirus for 48 hours in case of overexpression, and for 96 hours for sh-RNA-mediated knock-down. 
Echocardiography 
Echocardiography was performed after mice were anesthetized with 12 μl/g body weight of 
2.5% Avertin, as described previously 
2
. 
Prolonged ischemia 
Pathogen-free mice were housed in a temperature-controlled environment with 12 hr light/dark cycles, 
where they received food and water ad libitum. Mice were anesthetized by intraperitoneal injection of 
pentobarbital sodium (60 mg/kg). A rodent ventilator (model 683; 
Harvard Apparatus Inc) was used with 65% oxygen during the surgical procedure. The animals were 
kept warm using heat lamps and heating pads. Rectal temperature was monitored and maintained 
between 36.5 and 37.5°C. The chest was opened by a horizontal incision through the muscle between 
the ribs (third intercostal space). Ischemia was achieved by ligating the anterior descending branch of 
the left coronary artery (LAD) using an 8-0 nylon suture, with a silicon tubing (1 mm OD) placed on 
top of the LAD, 2 mm below the border between left atrium and left ventricle (LV). Regional ischemia 
was confirmed by ECG change (ST elevation).  
Assessment of area at risk and infarct size 
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After 3 hours of ischemia, the animals were reanesthetized and intubated, and the chest was opened. 
After arresting the heart at the diastolic phase by KCl injection, the ascending aorta was cannulated and 
perfused with saline to wash out blood. To demarcate the ischemic area at risk (AAR), Alcian blue dye 
(1%) was perfused into the aorta and coronary arteries. Hearts were excised, and LVs were sliced into 
1-mm thick cross sections. The heart sections were then incubated with a 1% 
triphenyltetrazolium chloride (TTC) solution at 37°C for 10 min. The infarct area (pale), the AAR 
(not blue), and the total LV area from both sides of each section were measured using ImageJ (NIH) 
and Adobe Photoshop (Adobe Systems Inc.), and the values obtained were averaged. The percentages 
of area of infarction and AAR of each section were multiplied by the weight of the section and then 
totaled from all sections. AAR/LV and infarct area/AAR were expressed as percentages. The extent of 
necrosis after 30 minutes of ischemia was quantified through Hairpin-2 staining (See below), since 
TTC staining is less accurate for the assessment of infarct size after this period of time
3
. 
High fat diet (HFD) mice feeding 
C57BL/6J wild-type mice, heterozygous Beclin-1 systemic knock-out mice, conditional mTOR knock-
out mice crossed with α-MHC-MerCreMer mice (C57BL/J background), and heterozygous GFP-LC3 
transgenic mice (C57BL/6J background, strain GFP-LC3#53, RIKEN BioResource Center) containing 
a rat LC3-GFP fusion under control of the chicken ß-actin promoter, were fed ad libitum with HFD 
(Research Diets D12492) for 18-20 weeks. A control group of mice matched for age and gender was 
fed with control diet for the same period of time. 
Mice hematochemical analysis 
Serum levels of glucose, cholesterol, triglycerides and non-esterified fatty acids (NEFA) in mice fed 
with control diet and high-fat diet were assessed by in vitro enzymatic colorimetric methods (Wako), 
according to the manufacturer’s instructions. Serum levels of insulin were assessed with an ELISA 
assay (Crystalchem).  
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Evaluation of apoptosis in tissue sections 
DNA fragmentation was detected in situ using the TUNEL assay, as described previously 
2
. 
Briefly, deparaffinized sections were incubated with proteinase K, and DNA fragments were labeled 
with fluorescein-conjugated dUTP using TdT (Roche Molecular Biochemicals). Nuclear density was 
determined by manual counting of DAPI-stained nuclei in six fields for each animal using the 40x 
objective, and the number of TUNEL-positive nuclei was counted by examining the entire section 
using the same power objective. 
TUNEL staining in cultured cardiomyocytes 
Myocytes were fixed in PBS containing 4% paraformaldehyde. Staining was performed using the 
In Situ Cell Death Detection kit (Roche). 
Assessment of necrosis in vivo with Hairpin-2 staining 
A double-stranded DNA fragment with blunt ends was prepared as previously described 
4, 5
. 
Polymerase chain reaction (PCR) with Pfu Ultra polymerase was performed with 16.6 μM Texas Red-
12-dUTP (Molecular Probes), 16.6 μM dTTP, 50 μM dATP, 50 μM dCTP and 50 μM dGTP. The Pfu 
probe recognizes a form of DNA damage characterized by cleavage of multiple DNA fragments with 
blunt ends, typically observed in necrotic cell death 
6
. Heart sections were deparaffinized with xylene, 
rehydrated in graded alcohol concentrations, briefly washed in water and then treated with proteinase K 
(50 µg/ml) in PBS for 45 minutes at 37°C. After washing with PBS, a mix of 50 mM Tris-HCl, pH 7.8, 
10 mM MgCl2, 10 mM, DTT, 1 mM ATP, 25 μg/ml BSA, 15% polyethylene glycol (8,000 mol wt, 
Sigma), 1 μg/ml Texas red-labeled DNA fragment and 250 U/ml DNA T4 ligase (Roche) was added. 
Sections were then placed in a humidified box for 16 hours. The sections were thoroughly washed in 
70°C water and observed under a fluorescent microscope immediately after counterstaining with 10 
μg/ml 4,6-diamidino-2-phenylindole (DAPI).  
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Cell size evaluation and histological analysis 
Heart specimens were fixed with 10 % neutral buffered formalin, embedded in paraffin, and sectioned 
at 6-μm thickness. Cell size was assessed through wheat germ agglutinin staining, as previously 
described 
2
. Immunofluorescent staining was performed with reagents and protocols previously 
described 
7
. Cardiac myocytes were stained with anti-troponin T antibody. Alexa 488- and Alexa 594-
conjugated secondary antibodies (Invitrogen) were used. Nuclei were stained with DAPI. 
Viability of the cells 
Viability of the cells was measured by Cell Titer Blue (CTB) assays (Promega). In sum, 
cardiomyocytes (1x10
5
 per 100 μl) were seeded onto 96-well dishes. After 24 hours, the medium was 
changed to a serum free medium. Cardiomyocytes were transduced with adenovirus harboring 
Rheb, Atg7 or LacZ for 36-48 hours, or shRNA against Rheb, TSC2, Beclin-1 or scramble shRNA for 
96 hours, and then changed to a glucose free medium for the time required by the experiment. Viable 
cell numbers were measured by the CTB assay. The CTB assays were performed according to the 
supplier's protocol. In vitro, necrosis was assessed through propidium iodide staining as previously 
described 
4
 
Evaluation of autophagy 
Autophagy was assessed by three different methods: LC3-II accumulation, p62 accumulation and 
autophagosome formation 
8, 9
. In vivo, LC3-II accumulation was evaluated in the early phase of 
ischemia (30 minutes), since LC3-II may be degraded and may not be reliable in the later phase 
9
. 
Autophagy in the later phase of ischemia was assessed by accumulation of p62, a protein known to be 
degraded by autophagy 
9
, since p62 accumulation represents a more stable marker of autophagy. 
Autophagosome formation in vivo was evaluated by counting GFP-LC3 dots in at least seven 
independent fields of heart sections from Tg-GFP-LC3 mice. These mice selectively express LC3 
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conjugated to a green fluorescent protein in the heart 
8
. GFP-LC3 dots were also evaluated after 
chloroquine administration (10 mg/kg i.p.) to evaluate autophagic flux, as previously described 
10
. 
For analysis of autophagosome formation in vitro, cardiomyocytes were grown on gelatinized 
coverslips. Myocytes were transduced with Ad-GFP-LC3, viruses that express GFP-LC3, for 48 hours. 
Samples were mounted using a SlowFade Light Antifade Kit (MolecularProbes), and the fluorescence 
of GFP-LC3 was observed under a fluorescence microscope. The number of cells with GFP-LC3 dots 
was counted in at least seven independent visual fields.  
Gene expression analysis 
mRNA expression of p62, atrial natriuretic factor (ANF) and GAPH (loading control) was evaluated 
with quantitative real time PCR, as described
4
. The following primers were used: p62 sense 5’-
CAGGCGCACTACCGCGATGA-3’, antisense 5’-TCGCACACGCTGCACAGGTC-3’; ANF sense 
5’-ATGGGCTCCTTCTCCATCAC-3’, antisense 5’-ATCTTCGGTACCGGAAGCTG-3’; and 
GAPDH sense 5’-TTCTTGTGCAGTGCCAGCCTCGTC-3’, antisense 5’-
TAGGAACACGGAAGGCCATGCCAG-3’; 
Immunoblot analysis, antibodies and reagents 
For immunoblot analyses, heart homogenates and cardiomyocyte lysates were prepared in a 
RIPA lysis buffer containing 50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 
0.1% SDS, 0.5% deoxycholic acid, 1 mM EDTA, 0.1 mM Na3VO4, 1 mM NaF, 50 
μM phenylmethylsulfonyl fluoride (PMSF), 5 μg/ml aprotinin and 5 μg/ml leupeptin. The 
antibodies used include anti-Rheb (Cell Signaling Technology and Santa Cruz), phospho-p70S6K 
(Thr389, Cell Signaling Technology), p70S6K (Santa Cruz), phospho-4E-BP1 (Thr37/46, Cell 
Signaling Technology), 4E-BP1 and mTOR (Cell Signaling Technology), TSC2 (Santa Cruz), p62 
(American Research Products, Inc.), LC3 (MBL), Bip (Cell Signaling Technology), phospho-PERK 
(Thr980, Cell Signaling Technology), CHOP (Santa Cruz), Caspase-12 and cleaved Caspase-3 (Cell 
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Signaling Technology), Beclin-1 (Pharmingen), Atg4 (MBL), Atg5 (MBL), Atg7 (MBL), Ulk1 
(Abcam), phospho-IR (Tyr11262/3, Santacruz), phospho-IRS1 (Tyr989, Ser636, Santacruz), IR and 
IRS-1 (Cell Signaling Technology), phospho-Akt1 (Ser473, Millipore), Akt1 (Cell Signaling 
Technology), GAPDH (Sigma) and tubulin (Sigma).  
Measurement of Rheb activity 
Endogenous Rheb activity is commonly evaluated by the ratio of GTP and GDP bound to Rheb, as 
Rheb is highly active when it is rich in GTP 
11
. Rheb-bound GTP and GDP amounts were assessed 
according to a previously described luminometric method 
12, 13
. This method represents a well-
established assay for the measurement of the activity of GTP-binding proteins 
14, 15
.  
Proteins were extracted from cultured cardiomyocytes or mouse heart specimens in an ice-cold 
HEPES-based buffer containing 10 mM MgCl2, protease inhibitors and 1% Igepal CA-630 
15
. The anti-
Rheb C antibody or control IgG was added to the samples, which were shaken at 4°C overnight in the 
presence of 500 mM NaCl, 0.5% deoxycholate and 0.05% SDS. Protein G-agarose was then added to 
each sample. After shaking for 2 hours at 4°C, the agarose beads were washed four times in lysis buffer 
containing NaCl and detergents, and two times in 20 mM TrisPO4, 5 mM Mg2SO4. The beads were 
resuspended in 20 mM TrisPO4, 1mM DTT, 1 mM EDTA, and heated at 100°C for 3 min to elute GTP 
and GDP bound to the immunoprecipitated Rheb. In each sample, GTP and the sum of GTP plus GDP 
were measured in coupled enzymatic assays 
15
. GTP was converted to ATP by nucleoside diphosphate 
kinase (3 mu) in the presence of ADP (10 pmol), and the resulting ATP was measured by the luciferase 
method (4 mmol of luciferin and 8x10
8
 light units of luciferase). The sum of GTP plus GDP was 
measured by converting GDP to GTP using pyruvate kinase (3 mu) and phosphoenolpyruvate (50 μM). 
GTP, which at this point represents the sum of GDP plus GTP, was measured as described above. The 
GTP/GTP+GDP ratio was then calculated by the ratio of the emitted light in the two reactions. 
Measurement of intracellular ATP content 
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Intracellular ATP content was measured using an ATP Bioluminescent Assay Kit (Sigma). 
Cells were scraped with PBS, and then half of them were used for protein content assay and the other 
half for ATP content measurement. For the latter assay, cells were lysed in the somatic-cell ATP-
releasing agent, and the lysates were assayed according to the manufacturer's instructions, using a 
1:625 dilution of the ATP assay mix. Light emitted was measured using a luminometer and was then 
normalized for protein content of the sample. For ATP content assays in myocardial tissue, heart 
specimens of equal weights were directly lysed in the somatic-cell ATP-releasing agent, and the lysates 
were assayed as described above. 
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Supplemental Tables 
Table I. Echocardiographic parameters of Tg-Rheb. 
 
 
 
 
 
 
 
 
 
 
 
SWTd: diastolic septum wall thickness; LVEDD: left ventricular end-diastolic diameter; PWTd: 
diastolic posterior wall thickness. Data is presented as (mean ± SEM). 
 
 Parameters 
NTg 
(N=4) 
Tg-Rheb 
(N=4) 
Echocardiographic 
parameters 
SWTd (mm) 0.91 ± 0.05 0.94 ± 0.03 
LVEDD (mm) 3.89 ± 0.10 3.92 ± 0.11 
PWTd (mm) 0.87 ± 0.05 0.89 ± 0.03 
SWTs (mm) 1.48 ± 0.11 1.51 ± 0.09 
LVESD (mm) 2.31 ± 0.11 2.29 ± 0.05 
PWTs (mm) 1.21 ± 0.05 1.30 ± 0.08 
FS (%) 40.49 ± 1.23 41.38 ± 1.05 
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Table II. Body weight and hematochemical tests in HFD mice as compared with CD mice. 
 
 
 
 
 
 
 
 
 
 
HOMA: Homeostatic Model Assessment; NEFA: not-esterified fatty acids. Data is presented as (mean 
± SEM); *p<0.05. 
Parameters 
Control diet 
(N=15) 
High fat diet 
 (N=15) 
Body weight (g) 26.8 ± 1.0 54.6 ± 3.3* 
Glucose (mg/dl) 112.9 ± 6.2 176.0 ± 17.3* 
Insulin (ng/ml) 0.23 ± 0.01 0.43 ± 0.02* 
HOMA Index 1.8 ± 0.22 5.8 ± 0.65* 
Total cholesterol 
(mg/dl) 
84.1 ± 3.1 126.1 ± 8.0* 
Tryglicerides 
(mg/dl) 
36.3 ± 3.7 71.2 ± 9.5* 
NEFA (meq/l) 0.93 ± 0.12 1.87 ± 0.35* 
 by MASSIMO BOTTICELLI on April 24, 2012http://circ.ahajournals.org/Downloaded from 
11 
 
Table III. Echocardiographic parameters of HFD mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control diet: CD; HFD: high fat diet; HW: heart weight; LVW: left ventricular weight; RVW: right 
ventricular weight; TL: tibia length; SWTd: diastolic septum wall thickness; LVEDD: left ventricular 
end-diastolic diameter; PWTd: diastolic posterior wall thickness. Data is presented as (mean ± SEM); 
*p<0.05. 
 Parameters 
CD 
(N=5) 
HFD 
(N=6) 
Gravimetric 
parameters 
HW/TL (mg/mm) 6.4 ± 0.3 8.2 ± 0.4* 
LVW/TL (mg/mm) 4.1 ± 0.1 5.9 ± 0.4* 
RVW/TL (mg/mm) 0.9 ± 0.03 1.3 ± 0.07* 
Lung/TL (mg/mm) 7.9 ± 0.15 7.4 ± 0.28 
Echocardiographic 
parameters 
SWTd (mm) 0.88 ± 0.03 1.08 ± 0.05* 
LVEDD (mm) 3.85 ± 0.08 4.12 ± 0.08 
PWTd (mm) 0.85 ± 0.05 1.00 ± 0.03* 
SWTs (mm) 1.31 ± 0.04 1.51 ± 0.05* 
LVESD (mm) 2.30 ± 0.06 2.55 ± 0.05 
PWTs (mm) 1.26 ± 0.04 1.47 ± 0.06* 
FS (%) 39.26 ± 1.04 38.61 ± 0.99 
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Supplemental Figure Legends 
Figure I. A, Rheb expression and phosphorylation status of p70
S6K
 were evaluated in cardiomyocytes 
transduced with adenovirus expressing a short hairpin sequence, targeting Rheb for 96 hours. B, 
Phosphorylation status of p70
S6K
 was evaluated in cardiomyocytes transduced with increasing doses of 
Ad-Rheb, after 4 hours of GD. C, Rheb was overexpressed in cardiomyocytes both at baseline and 
during GD, and it was then immunoprecipitated. Physical interaction between Rheb and mTOR was 
evaluated both at baseline and during glucose deprivation. D-F, Phosphorylation status of p70
S6K
 was 
evaluated in cardiomyocytes with sh-TSC2 depletion, sh-Rheb, or with sh-TSC2 (D) and sh-Rheb 
together (E). Densitometric quantification is also shown. N=4 (F). G-H, mTORC2 activity, as assessed 
by the phosphorylation status of Akt (Ser 473), was evaluated in cardiomyocytes transduced with Ad-
LacZ or Ad-Rheb, both at baseline and after 4 hours of GD. N=3.   
Figure II. A, Cardiomyocytes were transduced with Ad-LacZ or Ad Rheb for 48 hours, or with sh-
Rheb for 96 hours, and then subjected to GD for 18 hours. Percentage of propidium iodide-positive 
nuclei with respect to control cardiomyocytes was evaluated. N=3. B, Cardiomyocytes were transduced 
with sh-scramble or sh-TSC2 for 96 hours and then subjected to GD for 10 hours. TUNEL staining was 
performed. Data is presented as a percentage with respect to cells transduced with control adenovirus. 
Control bar is set at 100%. * p<0.05 vs. LacZ or Sh-CT. Bar=50 µm. N=3. 
Figure III. A-C, Cardiomyocytes were transduced with sh-scramble, sh-TSC2 or sh-Rheb for 96 
hours. LC3 isoforms and p62 accumulation were then evaluated at baseline or after 4 hours of GD. 
Representative immunoblots are shown (A), together with densitometric analyses of LC3-II (B) and 
p62 (C). N=4. D-E, Cardiomyocytes were coinfected with sh-scramble or sh-TSC2 for 96 hours and 
adenovirus expressing GFP-LC3 for the last 48 hours. After 4 hours of GD, GFP-LC3 puncta were 
counted. The percentage of cardiomyocytes with GFP-LC3 dots among those transduced with sh-
scramble or sh-TSC2 is shown (D, * p<0.05), together with representative images. N=5 (E, bar=10 
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µm). F-G, Cardiomyocytes were coinfected with sh-scramble or sh-Rheb for 96 hours and adenovirus 
expressing GFP-LC3 for the last 48 hours. The baseline percentage of cardiomyocytes with GFP-LC3 
dots among those transduced with sh-scramble or sh-Rheb is shown (F, * p<0.05; N=4), together with 
representative images (G, bar=10 µm).  
Figure IV. A, Atg7 expression levels were evaluated in cardiomyocytes transduced with Ad-LacZ or 
Ad-Atg7. B, LC3-II and p62 expression levels were evaluated in cardiomyocytes transduced with Ad-
LacZ, Ad-Rheb, or with Ad-Rheb together with Ad-Atg7. C-D, Cardiomyocytes were infected with 
Ad-GFP-LC3 together with Ad-LacZ or Ad-Rheb or Ad-Rheb and Ad-Atg7 together. Percentage of 
cardiomyocytes with GFP-LC3 puncta was evaluated during GD; bar=10 µm. N=3. E-F, Expression 
levels of LC3-II, p62, phospho-p70
s6k
, Atg7 and Beclin-1 were evaluated in Ad-LacZ- and Ad-Rheb-
transduced cardiomyocytes treated, or not treated, with trehalose.  
Figure V. A-B, Normalized cardiac Rheb expression was evaluated in double transgenic mice (Rheb
+
 
and tTA
+
; DTG) not treated with doxycycline, in DTG mice treated with doxycycline, and in 
Rheb
+
/tTA
-
 mice. Representative immunoblot is presented (A) with expression levels quantified (B). 
N=3; * p<0.05 vs. Dox(+) and tTA (-). C-D, LV myocardial tissue sections from control mice and Tg-
Rheb were stained with Rheb antibody (green fluorescence) and troponin T (red fluorescence), and 
then counterstained with DAPI (blue fluorescence) for nuclei visualization. Representative separate and 
merged panels from control (C) and Tg-Rheb (D) are presented. Bar= 50 µm. 
Figure VI. A-B, LV myocardial sections of Tg-Rheb and controls were subjected to TUNEL and 
DAPI staining. The percentage of cells that were TUNEL positive is shown. * p<0.05; N=3. 
Representative images of the staining in the border zone are shown (B, bar=50 µm). C-D, Tg-Rheb 
presented a higher necrosis rate after ischemia. LV myocardial sections were subjected to hairpin-2 and 
DAPI staining. The percentage of cells that were hairpin-2 positive is shown. * p<0.05; N=3 (C). 
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Representative images of the staining in the ischemic and non-ischemic areas are shown (D, bar=50 
µm). 
Figure VII. A-B, Tg-Rheb and control mice were subjected to 30 minutes of ischemia. The extent of 
myocardial necrosis was evaluated with Hapirpin 2 staining. The quantitative analysis of Hairpin 2 
staining is shown in A. Representative Hairpin 2 staining is shown in B  N=4. C-E, Tg-Rheb and 
control mice were subjected to 6 hours of ischemia. Representative images of the TTC staining/alcian 
blue staining is shown in C. Bar=50 µm. The quantitative analysis of AAR and MI size/AAR is shown 
in D and E, respectively.  
Figure VIII. A-C, Autophagy was evaluated in Tg-Rheb at baseline and after 30 minutes or 3 hours of 
ischemia, as assessed by LC3-II and p62 accumulation, respectively. A representative immunoblot is 
presented (A), together with the densitometric analyses of LC3 (B) and p62 (C). N=4 for each group. 
D, ATP content was assessed in the ischemic area of the left ventricles after 3 hours of ischemia. Data 
is presented as the percentages of respective baselines. Baseline is represented as one bar arbitrarily set 
at 100%. * p<0.05 with respect to relevant baseline. N=5. E-F, Cardiac CHOP expression was 
evaluated in Tg-Rheb and controls at baseline and after 3 hours of ischemia. A representative blot is 
shown (E), together with the densitometric analysis; N=5 for each group (F). 
Figure IX. A, Phosphorylation status of insulin receptor β (Tyr1162/3), phosphorylation of insulin 
receptor substrate-1 (Tyr989, Ser 636), and phosphorylation of Akt1 (Ser473) were evaluated in HFD 
mice and compared to control animals. B-C, Cell size was evaluated through WGA staining in the 
heart of HFD mice with respect to controls. Cell size quantification is presented as fold vs. control, 
which is set at 1. * p<0.05. In C, Representative images are also presented. N=4. Bar=50 µm. D, ANF 
expression resulted to be increased in HFD mice with respect to controls. Data is presented as fold vs. 
CD mice. * p<0.05. N=6. 
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Figure X. A-B, HFD mice presented a higher apoptosis rate in the ischemic area after ischemia. LV 
myocardial sections were subjected to TUNEL and DAPI staining. The percentage of cells that were 
TUNEL-positive is shown. * p<0.05; N=3 (A). In B, representative images of the staining in the border 
zone are shown. Bar=50 µm. C-D, HFD mice presented a higher necrosis rate after ischemia. LV 
myocardial sections were subjected to hairpin-2 and DAPI staining. The percentage of cells that were 
hairpin-2 positive is presented. * p<0.05; N=3. In D, Representative images of the staining in the 
ischemic and non-ischemic areas are shown. Bar=50 µm. 
Figure XI. A, HFD mice present an increase in phosphorylation status of p70
S6K 
and AMPK in the 
heart. Representative immunoblots are presented in Fig. 7D. N=4 for each group. B-C, Myocardial 
autophagy in obese mice was significantly inhibited compared to that in lean mice, both at baseline and 
after 30 minutes or 3 hours of ischemia, as indicated by LC3-II and p62 accumulation, respectively. 
N=4 for each group. Representative immunoblots are presented in Figure 7F. D-E, Chloroquine (10 
mg/kg) was administered to Tg-GFP-LC3 mice fed with control diet or HFD, 4 hours before surgery. 
After 30 minutes of ischemia, GFP-LC3 puncta were counted in LV sections. In D, representative 
images are presented. Bar=50 µm. In E, quantification of the number of dots/field is shown. N=3. F, 
Rapamycin (1 mg/kg) was administered intraperitoneally to HFD and CD mice 60 minutes before 
coronary ligation. After 30 minutes of ischemia, autophagy was evaluated by LC3-II accumulation in 
the hearts of HFD mice treated with rapamycin, with respect to HFD mice treated with vehicle.  
Figure XII. A, Tamoxifen (30 g/g) was administered to α-MHC-MerCreMer-mTOR flox/+ mice 
(mTOR+/-) and α-MHC-MerCreMer-mTOR +/+ mice (controls) for 7 days. Cardiac mTOR protein 
levels were evaluated in mTOR+/- and controls 3 weeks after tamoxifen administration. B-D, Cardiac 
phosphorylation status of p70
S6K
, and LC3-II accumulation were evaluated in mTOR+/- mice and 
controls, fed with control diet or HFD (N=4). * p<0.05 vs. CT. E, A schematic representation of our 
hypothesis. Nutrient starvation and prolonged ischemia inhibit the mTORC1 pathway through Rheb 
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inhibition. Rheb/mTORC1 inhibition upregulates autophagy, which increases cardioprotection. On the 
other hand, obesity and metabolic syndrome activate the Rheb/mTORC1 pathway during prolonged 
ischemia, causing a defective activation of autophagy and a reduction in cardioprotection.  
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